BIOGEN’S SPINRAZA® RECEIVES RECOMMENDATION FROM NICE FOR THE TREATMENT OF INFANTS, CHILDREN AND ADULTS WITH 5q SPINAL MUSCULAR ATROPHY

109

MAIDENHEAD, England–(BUSINESS WIRE)–The National Institute for Health and Care Excellence (NICE) has recommended funding for Spinraza (nusinersen) on the National Health Service (NHS). The positive recommendation, subject to a five-year managed access agreement (MAA), is for the treatment of infants, children and adults with 5q spinal muscular atrophy (SMA), including pre-symptomatic and SMA types I, II and III. SMA is a rare, debilitating and life-threatening disease that results in severe p…

 

 

 

 

READ MORE: http://www.businesswire.com/news/home/20190514006045/en/BIOGEN%E2%80%99S-SPINRAZA%C2%AE%E2%96%BC-NUSINERSEN-RECEIVES-RECOMMENDATION-NICE-TREATMENT/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==

- Advertisement -